Contents:

Executive Summary Strategic Considerations Stakeholder Implications Introduction Overview of Sjögren’s Syndrome Disease Description and Etiology Diagnosis Clinical Manifestations Dry Mouth Dry Eye Other Symptoms Epidemiology Overview Methods Current Therapies for Sjögren’s Syndrome Current Treatments for Dry Eye in Sjögren’s Syndrome Allergan/Inspire Pharmaceutical’s Restasis Punctal-Plug Treatments Current Treatments for Dry Mouth in Sjögren’s Syndrome Eisai/Kissei Pharmaceutical’s Salagen Daiichi Sankyo’s Evoxac Current Treatments for Systemic Symptoms of Sjögren’s Syndrome Hydroxychloroquine Methotrexate Azathioprine Emerging Therapies for Sjögren’s Syndrome Systemic Treatments for Sjögren’s Syndrome Rituxan/MabThera (rituximab) Epratuzumab Remicade (infl iximab) Enbrel (etanercept) Other TNF-a Inhibitors Emerging Therapies for Dry Eyes in Sjögren’s Syndrome Prolacria (diquafosol tetrasodium; ophthalmic solution) Ecabet Sodium (ophthalmic solution) Rebamipide (ophthalmic suspension) Emerging Therapies for Dry Mouth in Sjögren’s Syndrome NGX-267 Outlook for the Sjögren’s Syndrome Market Appendix A: Bibliography Tables 1. Comparison of Diagnostic Criteria for Sjögren’s Syndrome 2. Current Therapies for Sjögren’s Syndrome 3. Emerging Therapies for Sjögren’s Syndrome, 2008 Figures: 1. Rheumatologists’ Estimate of the Prevalence of Sjögren’s Syndrome Symptoms 2. Prevalent Cases of Sjögren’s Syndrome, 2007-2017 3. Survey Question: Please indicate your first-, second-, and third-line therapy for the treatment of Sjögren’s syndrome-associated dry eye 4. Survey Question: Please indicate your first-, second-, and third-line therapy for the systemic treatment of Sjögren’s syndrome 5. Survey Question: If Rituxan’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe Rituxan to your patients? 6. Survey Question: What agents do you believe are most likely to be replaced by Rituxan? 7. Survey Question: If epratuzumab’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe epratuzumab to your patients? 8. Survey Question: What agents do you believe are most likely to be replaced by epratuzumab? 9. Survey Question: If Remicade’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe Remicade to your patients 10. Survey Question: If Prolacria’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe Prolacria to your patients 11. Survey Question: What agents do you believe are most likely to be replaced by Prolacria? 12. Survey Question: If ecabet sodium’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe ecabet sodium to your patients 13. Survey Question: If NGX-267’s effi cacy in treating Sjögren’s syndrome can be established, will you prescribe NGX-267 to your patients

Companies Mentioned

- Abbott Laboratories - Acucela - Allergan - Amgen - Biogen Idec - Centocor - Chugai Pharmaceutical - Daiichi Sankyo - Dava Pharmaceuticals - Eisai - Genentech - GlaxoSmithKline - Immunomedic - Inspire Pharmaceuticals - Ista Pharmaceuticals - Kissei Pharmaceutical - Mitsubishi Tanabe Pharma - Otsuka Pharmaceutical - Roche - Salix Pharmaceuticals - Sanofi -Aventis - Santen Pharmaceutical - Schering-Plough - Takeda - TorreyPines Therapeutics - UCB - Wyeth - Zenyaku Kogyo